(CIDRAP News) A comprehensive review of the nation's tools for reducing the impact of a biological weapons attack or other public health emergencyprompted in part by last fall's delays in delivery of the pandemic H1N1 vaccineis due to get under way in the next few weeks with a pair of conferences.
Editor's note: This story was revised after initial posting to specify which arm of the CDC issued the statement described.
(CIDRAP News) Officials at the Centers for Disease Control and Prevention (CDC) yesterday rejected a contention from several professional groups that its guidance on respiratory protection for healthcare workers caring for H1N1 patients was influenced by a recent controversial study by Australian researchers.
A reanalysis prompted by reviewers has changed the conclusions of a study comparing N-95 respirators with surgical masks, raising questions about earlier findings that the N-95 devices were clearly more effective in protecting healthcare workers from respiratory illness.
(CIDRAP News) The US Centers for Disease Control and Prevention (CDC) today issued eagerly awaited recommendations on pandemic H1N1 infection control in healthcare settings, which affirms its earlier guidance on N-95 respirators but spells out other options for when the respirators are in short supply.
(CIDRAP News) – In findings sure to renew the continuing controversy over respiratory protection for healthcare workers, surgical masks appeared to protect hospital nurses from influenza about as well as N-95 respirators did in a randomized trial conducted in Ontario.
(CIDRAP News) Eighteen medical groups, led by the American Medical Association (AMA) and the American Public Health Association (APHA), released a report at a recent conference in Washington, DC, that contains 53 recommendations for improving the nation's response to mass casualty events such as terrorist attacks, infectious disease outbreaks, and natural disasters.
(CIDRAP News) A study involving tens of thousands of children has strengthened the evidence that influenza vaccination is safe for those 6 to 23 months old, an age-group for whom the government began recommending flu immunization 2 years ago.
(CIDRAP News) Almost 5 years ago, the American Academy of Pediatrics (AAP) and the US Public Health Service joined in calling for removal of the mercury-containing preservative thimerosal from vaccines. By 2001, all the vaccines recommended for children under age 7 were available without thimerosal or with only trace amounts.